OICR is an innovative translational research institute dedicated to research on the prevention, early detection, diagnosis and treatment of cancer.
Read the Annual Report: PDF [24 MB]
Collaboration leads to better research and improved outcomes for cancer patients
Read the report
Our alliance of over 150 organizations in over 20 countries is collaborating to share knowledge and best practices, to benefit medicine and human health. - Dr. Tom Hudson
Find out more
OICR's research focuses on areas with the greatest potential impact on patients.
OICR’s funding from its partners and the Government of Ontario is $160 million, which supports more than 1,600 researchers, clinician-scientists, research staff and trainees.
OICR provides expertise and funding to help researchers further develop and commercialize their cancer research and technologies.
The ICGC is designed to identify cancer-causing mutations involved in more than 25,000 tumours for more than 50 types of cancer.
Learn more about OICR's programs, funding opportunities and careers.
Dr. John Bell and his collaborators are developing an innovative oncolytic vaccine strategy using an oncolytic virus derived from the Maraba virus.
Read the story
To learn more about OICR's job opportunities, please visit our Careers page.
Learn more about OICR's commercialization program, IPDC Fund and investment opportunities.
Get an inside look at OICR: Dr. David Uehling explains how he became a chemist and why he focused on cancer research.
View the video
Learn more about OICR's research, leadership, the latest news items and contact information.
© 2013 Ontario Institute for Cancer Research. All rights reserved.
Funding for the Ontario Institute for Cancer Research is provided by the Government of Ontario